Talampanel for Amyotrophic Lateral Sclerosis (ALS) (ALS)
A Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Tolerability and Safety of Talampanel in Subjects With Amyotrophic Lateral Sclerosis (ALS)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Leuven, Belgium, B-3000
- Academic Hospital University of Leuven - ALS dept
-
-
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 2G9
- ALS Centre
-
-
Ontario
-
London, Ontario, Canada, N6A 5A5
- London Health Sciences Centre Motor Neuro Diseases Clinic
-
-
Quebec
-
Montreal, Quebec, Canada, H3A 2B4
- Montreal Neurological Institute
-
-
-
-
-
Marseille Cedex 5, France, 13385
- C.H.U. La Timone - Service de Neurologie
-
Montpellier Cedex 5, France, 34295
- C.H.U. de Montpellier - Hopital Gui de Chauliac - Service des Explorations Neurologiques
-
Paris, France, 75013
- Hopital La Pitie Salpetriere - Federation de Neurologie
-
-
-
-
-
Berlin, Germany, 13353
- Universitaetsklinik Berlin-Charite, Campus Virchow Klinikum, Neurologische Klinik
-
Bochum, Germany, 44789
- Berufsgenossenschaftliche Klinik Bergmannsheil, Neurologische Klinik
-
Ulm, Germany, 89081
- Universitaet Ulm
-
-
-
-
-
Budapest, Hungary, 1083
- Semmelweis University, Department of Neurology
-
-
-
-
-
Tel Aviv, Israel, 64239
- Sourasky MC -EMG Unit
-
-
-
-
-
Lissone (MI), Italy, 20035
- Fondazione "S.Maugeri" Clinica della Riabilitazione IRCCS-Istituto Scientifico di Lissone
-
Milano, Italy, 20162
- Centro Clinico NeMO
-
Torino, Italy, 10126
- Azienda Ospedaliero Universitaria San Giovanni Battista di Torino - Dipartimento di Neuroscienze
-
-
-
-
-
Utrecht, Netherlands, 3584 CX
- Universitair Medisch Centrum Utrecht
-
-
-
-
-
Madrid, Spain, 28029
- Hospital Carlos III
-
-
-
-
California
-
San Francisco, California, United States, 94115
- CA Medical Center for Movement Disorders-Forbes Norris MDA/ALS Research Center
-
-
Kansas
-
Kansas City, Kansas, United States, 66160
- University of Kansas Medical Center - Dept of Neurology
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Johns Hopkins OPC - Meyer Bldg
-
-
Massachusetts
-
Charlestown, Massachusetts, United States, 02129
- Massachusetts General Hospital-Neurology Clinical Trials Unit
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
New York
-
New York, New York, United States, 10032
- Columbia University - Neurology Institute
-
Syracuse, New York, United States, 13210
- SUNY Upstate Medical University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Subjects with sporadic or familial ALS classified as definite, probable, or laboratory-supported probable ALS according to the revised El Escorial criteria.
Inclusion Criteria:
- Diagnosis of definite or probable ALS in accordance with the El-Escorial criteria.
- Subject has experienced his/her first ALS symptoms within 3 years prior to the screening visit.
- Slow VC test equal to or greater than 70% of the predicted value.
- The sum of the 3 respiratory items on the ALSFRS-R must total at least 10 points.
- Subjects taking riluzole must be on a stable dose for at least 8 weeks prior to screening visit.
- Ages 18-80 (inclusive)
Exclusion Criteria:
- The use of invasive or non-invasive ventilation.
- Subject having undergone gastrostomy.
- Subject with any clinically significant or unstable medical condition.
- Subject participating in any other investigational drug trial or using investigational drug (within 12 weeks prior to screening and thereafter).
- Females who are pregnant or nursing.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Talampanel 50mg
50mg Talampanel 3 times per day
|
capsules Talampanel, 3 times per day, 52 weeks
Other Names:
|
|
Experimental: Talampanel 25mg
25mg Talampanel 3 times per day
|
capsules Talampanel, 3 times per day, 52 weeks
Other Names:
|
|
Placebo Comparator: Placebo
placebo 3 times per day
|
capsules, placebo, 3 times a day, for 52 weeks
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change in ALS Functional Rating Score (ALSFRS-R slope)
Time Frame: 52 weeks
|
52 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Time from baseline to the first occurrence of either death, tracheostomy or permanent assisted ventilation.
Time Frame: 52 weeks
|
52 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Metabolic Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neuromuscular Diseases
- Neurodegenerative Diseases
- Spinal Cord Diseases
- TDP-43 Proteinopathies
- Proteostasis Deficiencies
- Motor Neuron Disease
- Amyotrophic Lateral Sclerosis
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Excitatory Amino Acid Agents
- Excitatory Amino Acid Agonists
- alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid
Other Study ID Numbers
Other Study ID Numbers
- ALS-TAL-201 (ALSTAR)
- ALSTAR
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.